Home › Prostate Cancer › NCT07096999

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Who can join

Ages 18 and older · Men

Inclusion Criteria:

* \* 177Lu-617 PSMA treatment scheduled for mCRPC

  * Clinically stable as determined by the nuclear medicine clinicians
  * Male
  * ≥ 18 years of age
  * Willing and able to provide informed consent

Exclusion Criteria:

* Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

About the study

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

What is being tested

• Non-Interventional Study (other)

Sponsor: University of Michigan Rogel Cancer Center · Participants: 60 · Started: Jan 23, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07096999

Locations in the U.S.

Conditions

• Prostate Cancer

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.